Teon Therapeutics names Serge Messerlian as CEO

Privately-held US biotech Teon Therapeutics has announced the appointment of Serge Messerlian as chief executive and member of the board of directors.

Mr Messerlian will assume the role from co-founder, acting CEO and chief scientific officer (CSO), Dr Lina Yao, who remains as CSO. Dr Yao will continue as a member of the board of directors.

Mr Messerlian brings to the role significant experience in the industry, across a range of roles and therapeutic areas including hematology, oncology, immunology, and rare diseases. He joins Teon from Janssen Oncology US, a subsidiary of Johnson & Johnson (NYSE: JNJ), where he served as president and set the strategic direction for the organization and its key brands across hematology and solid tumors.